BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 20, 2017
View Archived Issues
Rich Pharmaceuticals signs agreement to support HypGen's development of Parkinson's treatments
Read More
Mallinckrodt completes license transfer of Synacthen Depot to West Pharmaceuticals
Read More
Managed access program launched for eteplirsen to treat DMD amenable to exon 51 skipping
Read More
Sacituzumab govitecan demonstrates an effective therapeutic profile in patients with mSCLC
Read More
Johnson & Johnson offers overview of second quarter 2017
Read More
LabCorp makes ADAMTS13 test available in U.S.
Read More
Grant to support OSE's development of new immune checkpoint inhibitor OSE-172
Read More
MEDI-1814 suppresses Abeta42 levels in animal studies
Read More
Ablynx collaborates with Sanofi on Nanobody therapeutics for immune-mediated inflammatory diseases
Read More
Celyad initiates phase I study of CYAD-01 in metastatic colorectal cancer
Read More
Phase III safety results on revefenacin for COPD to support NDA submission
Read More
BACE1 inhibitor JNJ-54861911 suppresses beta-amyloid in animal models
Read More
Bayer Pharma patents IRAK-4 inhibitors
Read More
Mission Therapeutics divulges deubiquitylating enzyme inhibitors
Read More
Gruenenthal discloses PDE4B inhibitors
Read More
Immune Pharmaceuticals continues plan to spin off Cytovia
Read More
Chiesi Farmaceutici presents MAPK inhibitors
Read More
IMG-7289 advances into phase IIa portion of trial in AML and MDS
Read More
Rolling NDA submission completed for CAM-2038 to treat opioid use disorder
Read More
FDA accepts for review Hizentra sBLA for chronic inflammatory demyelinating polyneuropathy
Read More
Marina Biotech enters license agreement for use of SMARTICLES to deliver antisense DNA therapeutics
Read More
Aerie reports 12-month safety data from Roclatan registration trial
Read More
European approval for Kyntheum for moderate to severe plaque psoriasis
Read More